Acadia pharmaceuticals announces positive top-line results from the pivotal phase 3 lavender trial of trofinetide in rett syndrome

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced positive top-line results from the pivotal, phase 3 lavender™ study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with rett syndrome. the 12-week placebo-controlled study demonstrated a statistically significant improvement over placebo for both co-primary endpoints. on the rett syndrome behaviour questionnaire (rsbq), change from baseline to week 12 was -5.1 v
ACAD Ratings Summary
ACAD Quant Ranking